- Home
- CCEC vs COLL Comparison
CCEC vs COLL Comparison
Compare CCEC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- COLL
- Stock Information
- Founded
- CCEC 2007
- COLL 2002
- Country
- CCEC Greece
- COLL United States
- Employees
- CCEC N/A
- COLL N/A
- Industry
- CCEC Marine Transportation
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- COLL Health Care
- Exchange
- CCEC Nasdaq
- COLL Nasdaq
- Market Cap
- CCEC 1.1B
- COLL 1.1B
- IPO Year
- CCEC 2007
- COLL 2015
- Fundamental
- Price
- CCEC $18.79
- COLL $29.58
- Analyst Decision
- CCEC Buy
- COLL Strong Buy
- Analyst Count
- CCEC 1
- COLL 6
- Target Price
- CCEC $22.00
- COLL $42.00
- AVG Volume (30 Days)
- CCEC 23.4K
- COLL 440.1K
- Earning Date
- CCEC 11-08-2024
- COLL 11-07-2024
- Dividend Yield
- CCEC 3.19%
- COLL N/A
- EPS Growth
- CCEC N/A
- COLL 757.11
- EPS
- CCEC 0.85
- COLL 2.16
- Revenue
- CCEC $447,305,000.00
- COLL $599,245,000.00
- Revenue This Year
- CCEC N/A
- COLL $13.02
- Revenue Next Year
- CCEC N/A
- COLL $18.01
- P/E Ratio
- CCEC $76.15
- COLL $13.68
- Revenue Growth
- CCEC 29.66
- COLL 9.62
- 52 Week Low
- CCEC $13.10
- COLL $25.07
- 52 Week High
- CCEC $20.26
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- COLL 26.96
- Support Level
- CCEC N/A
- COLL $29.69
- Resistance Level
- CCEC N/A
- COLL $35.62
- Average True Range (ATR)
- CCEC 0.00
- COLL 1.41
- MACD
- CCEC 0.00
- COLL -0.39
- Stochastic Oscillator
- CCEC 0.00
- COLL 6.36
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.